We hope that using the genomic diagnostics and addressing the unique somatic and germline variants early in a patient’s journey, the physician can help enhance and potentially extend their patient’s life.
Houston, Tx (PRWEB) May 28, 2015
CompanionDx, a Houston-based genomic diagnostic and decision support company, announces that it will present their integrated solution of next-generation sequencing (NGS) and pharmacogenomics (PGx) testing at the annual American Society of Clinical Oncology (ASCO) in Chicago this weekend.
Next-generation sequencing evaluates the DNA in a patient’s tumor via a small biopsy sample. The DNA is analyzed for key changes or somatic mutations. Pharmacogenomics testing establishes a clear understanding of the patient’s potential for metabolizing a drug based on their possible germline variants. The germline cells contain the inheritable genetic materials that can be passed on in generations. Germline variations play an important role in how oncology drugs are metabolized.
“CompanionDx has recently integrated our genomic diagnostics to help provide physicians and patients with actionable and comprehensive reports to help physicians make therapy decisions,” said Michael Stewart, CEO of CompanionDx. “The specific diagnostic reports should enable physicians to quickly make decisions and identify appropriate therapies.”
As a part of the integrated solution, physicians have access to CompanionDx’s call center to help with the implications of therapies for the patient and drug monitoring services in the event that adjustments are needed.
“We hope that using the genomic diagnostics and addressing the unique somatic and germline variants early in a patient’s journey, the physician can help enhance and potentially extend their patient’s life,” noted Stewart.
# # #
CompanionDx is the integrated genomic diagnostic and decision support company. Headquartered in Houston, CompanionDx is committed to enhancing and extending patients’ lives by providing physicians with the actionable intelligence they need. Only CompanionDx has the integrated genomic solutions, combining diagnostics such as next-generation sequencing, pharmacogenomics and therapeutic drug monitoring. CompanionDx’s certified molecular biologists, pathologists and technologists conduct all tests within two high-complexity, CLIA-certified labs, while continually seeking ways to improve the approach to patient therapy. From tumor diagnosis to treatment, CompanionDx delivers the clinical insight physicians need while continuing to advance the field with data intelligence. For more information about how CompanionDx is redefining the patient journey, visit http://www.companiondxlab.com.